Biopharmaceutical company Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) announced a weaker than predicted financial results for the first quarter. The company suffered a net loss of $92.7 million or a loss of $1.58 a share for the first quarter versus a profit of $43.4 million or 71 cents a share in the year earlier quarter. However, on an adjusted basis, profit grew 19.3% to $100.8 million from $84.4 million and the earnings per share increased 17.5% to $1.61 from $1.37 in the year-ago quarter. On average, analysts predicted the company to earn $1.79 a share. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) net profit margin is 24.80% and weekly performance is -8.28%. On last trading day company shares ended up $130.23. Analysts mean target price for the company is $177.07. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) distance from 50-day simple moving average (SMA50) is -7.69%.
U.S. drugmaker Allergan Inc on Monday rejected Valeant Pharmaceuticals International Inc. (NYSE:VRX) $47 billion takeover offer, saying its proposed cost cuts were too steep. Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) shares fell -0.77% in last trading session and ended the day on $130.16. VRX gross Margin is 67.00% and its return on assets is -3.70%.Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) quarterly performance is -5.77%.
Swiss drug maker Roche Holding AG (OTCMKTS:RHHBY) reported a 1% dip in first-quarter revenue as the strong Swiss franc eroded the value of growing sales of its cancer drugs. Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) shares moved up 0.14% in last trading session and was closed at $36.15, while trading in range of $35.90 – $36.16.
GlaxoSmithKline PLC (ADR) (NYSE:GSK) said Tuesday its Phase III study for drug darapladib in the treatment of acute coronary syndrome failed to meet its primary endpoint of reducing major coronary events compared to a placebo when added to standard care. GlaxoSmithKline plc (ADR) (NYSE:GSK) ended the last trading day at $55.14. Company weekly volatility is calculated as 0.76% and price to cash ratio as 22.09.GlaxoSmithKline plc (ADR) (NYSE:GSK) showed a negative weekly performance of -0.27%.
Abbott (NYSE:ABT) announced initial results that suggest its innovative testing platform, known as IRIDICA (currently in development), produces results consistent with the current standard of care in just hours. Abbott Laboratories (NYSE:ABT) shares moved up 0.72% in last trading session and was closed at $39.27, while trading in range of $39.03 – $39.38. Abbott Laboratories (NYSE:ABT) year to date (YTD) performance is 3.64%.
Leave a Reply